Varadi G, Or R, Rund D, Orbach H, Slavin S, Nagler A
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Bone Marrow Transplant. 1995 Dec;16(6):843-5.
CAMPATH-1G is an IgG2b rat antihuman (CDw52) monoclonal antibody (MoAb) which is currently being used for T cell depletion in the setting of allogeneic bone marrow transplantation (BMT). In addition it elicits substantial lymphoid depletion, an effect which is being explored for remission induction in patients with lymphoid malignancies and for treating patients with various autoimmune disorders, in particular rheumatoid arthritis. Recently, in vivo CAMPATH-1G has been introduced to achieve increased immunosuppression in the pretransplant conditioning, for prevention of graft rejection following T cell depleted BMT. Here we describe a patient with T cell lymphoblastic lymphoma who received in vivo CAMPATH-1G as part of the pretransplant conditioning regimen and who, 6 days after the first dose, developed severe migratory polyarthritis. This is the first report of severe migratory polyarthritis as a very unusual complication following CAMPATH-1G MoAb administration.
CAMPATH-1G是一种IgG2b大鼠抗人（CDw52）单克隆抗体（MoAb），目前用于异基因骨髓移植（BMT）中的T细胞清除。此外，它还能引起显著的淋巴细胞清除，这种效应正在被探索用于诱导淋巴系统恶性肿瘤患者的缓解以及治疗各种自身免疫性疾病患者，特别是类风湿性关节炎。最近，体内应用CAMPATH-1G已被用于在移植前预处理中增强免疫抑制，以预防T细胞清除后的骨髓移植中的移植物排斥。在此，我们描述了一名患有T细胞淋巴母细胞淋巴瘤的患者，该患者在移植前预处理方案中接受了体内CAMPATH-1G治疗，在首次给药6天后出现了严重的游走性多关节炎。这是关于CAMPATH-1G单克隆抗体给药后出现严重游走性多关节炎这一非常罕见并发症的首次报告。
